Genosys Bio - we're a London based (SF soon!) startup. We teach our models the regulatory language of DNA and use it to make synthetic 'volume controls' that let us make more of an antibody and less of a toxin.
The cool thing is since we don't change the structure/activity of an antibody it doesn't require the usual 1B + 13 years of clinical trials. Instead we cut down on the amount of times it takes and also increase production yields.
Do add me me on linkedin (Taiga Clarke) if there might be some synergy there :)